SignaCor, a clinical stage drug development company spun-out from Queen’s University Belfast, has successfully secured $337,000 in new investment capital. This funding round marks a significant milestone for the company, which is dedicated to advancing treatments for cardiac disease. The capital infusion will support SignaCor's ongoing efforts to develop innovative therapeutic solutions, particularly for symptomatic hypertrophic cardiomyopathy (HCM).
The company is pioneering a first-in-class therapeutic approach to symptomatic HCM, aiming to go beyond conventional symptom management to target the underlying disease pathology. SignaCor's lead candidate, Cardiaza, represents a novel treatment that harnesses DNA methylation. This approach is designed to address multiple underlying causes of symptomatic HCM, including established fibrosis, which is a key driver of disease progression.
The $337,000 investment is crucial for SignaCor as it prepares for its next phase of development. The funds are expected to primarily support the company's operational growth and the progression of its clinical programs. Specifically, this capital will contribute to the preparations for the planned Phase 2a clinical trial for Cardiaza, which is scheduled to commence in 2025. This trial is a critical step in validating the efficacy and safety of SignaCor's therapeutic strategy.
With this new funding, SignaCor is well-positioned to accelerate its research and development initiatives. The company remains focused on its mission to bring a transformative treatment to patients suffering from symptomatic hypertrophic cardiomyopathy, aiming to address a significant unmet medical need in cardiac care. This investment underscores confidence in SignaCor's scientific foundation and its potential to impact the future of cardiac disease treatment.
